DHEA inhibits the Src/STAT3 constitutive activation
Oct 4th, 2011 by ajphearteditor
Pulmonary hypertension affects millions of patients with increasing prevalence each year, and clinical treatments are still in their infancy. In our latest podcast, Associate Editor Leon de Windt talks with senior author Sebastien Bonnet (Universite Laval) and leading expert Laura Gonzalez Bosc (University of New Mexico) about the article by Paulin et al, which reports the first demonstration of DHEA blocking two major transcription factors—STAT3 and NFAT. Is DHEA, a commercially available natural steroid hormone and antioxidant, the newest entry point for pharmacological intervention and treatment of pulmonary hypertension? Listen in and find out.
Roxane Paulin, Jolyane Meloche, Maria Helena Jacob, Malik Bisserier, Audrey Courboulin, and Sebastien Bonnet. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol, published ahead of print September 2, 2011, doi:10.1152/ajpheart.00654.2011.